Effects of early recombinant human growth hormone treatment in young Chinese children with Prader–Willi syndrome

Orphanet Journal of Rare Diseases

Research

Li-Li Yang¹  Ying Gao¹  Yang-Li Dai¹  Zheng Shen¹  Chao-Chun Zou¹  Qiong Zhou² 

[1] The Children’s Hospital of Zhejiang University School of Medicine, No. 3333 Binsheng Road, 310051, Hangzhou, China;The Children’s Hospital of Zhejiang University School of Medicine, No. 3333 Binsheng Road, 310051, Hangzhou, China;Hangzhou children’s Hospital, No. 195 Wenhui Road, 310000, Hangzhou, China;

关键词: Prader–Willi syndrome;    Growth hormone;    Body composition;    Length;    Height;    Carbohydrate metabolism;    Spinal deformity;   

DOI  :  10.1186/s13023-023-02615-7

 received in 2022-05-30, accepted in 2023-01-15,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundPrader–Willi syndrome (PWS) is a rare and multisystemic genetic disorder that is characterized by severe hypotonia, hyperphagia, short stature, and global developmental delay. Although early recombinant human growth hormone (rhGH) treatment has been proven to rescue some symptoms and bring additional benefits to PWS patients, studies in patients under 2 years old are scarce. Thus, this study aims to investigate the effectiveness and safety of rhGH treatment for young children.MethodsA total of 96 genetically confirmed Chinese PWS infants or toddlers (47 males) followed between 2013 and 2022 were retrospectively analyzed. Sixty-five infants (early treatment group) started rhGH treatment during their first year, and 31 toddlers (later treatment group) started at the age of 1–2 years. Auxological parameters, carbohydrate metabolism parameters, thyroid function, liver function, insulin-like growth factor-1 (IGF-1), and radiographs were acquired before the initiation of the treatment and every 3–6 months thereafter. Height/length, weight, and weight for height were expressed as standard deviation scores (SDSs) according to WHO child growth standards.ResultsThe mean SDS of length/height in the early treatment group was significantly higher than that in the later treatment group throughout the observation period (all P < 0.001). The change in the length SDS between the two groups at 1 year old and 4 years old was 1.50 (95% CI, 0.88–2.13) and 0.63 (95% CI, 0.16–1.10), respectively. Compared to the later treatment group, the weight SDS in the early treatment group increased by 0.94 (95% CI, 0.37–1.52) at 1 year old and 0.84 (95% CI, 0.28–1.39) at 2 years old. No statistical significance was found after 2.5 years of age. No significant differences were observed in IGF-1, incidence of liver dysfunction, hypothyroidism or spinal deformity between the two groups.ConclusionsrhGH treatment improved growth and body composition in infants and toddlers. Furthermore, an early start of rhGH treatment is expected to have more efficacy than the later treatment group without an increase in adverse effects.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 2

40463_2023_625_Article_IEq5.gif